PMID- 27066091
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160412
LR  - 20240325
IS  - 1738-6756 (Print)
IS  - 2092-9900 (Electronic)
IS  - 1738-6756 (Linking)
VI  - 19
IP  - 1
DP  - 2016 Mar
TI  - Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice 
      Guide.
PG  - 8-17
LID - 10.4048/jbc.2016.19.1.8 [doi]
AB  - Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the 
      treatment of pretreated metastatic breast cancer (mBC) based on the positive 
      outcomes of phase II and phase III clinical trials, which enrolled mainly Western 
      patients. Eribulin has recently been approved in an increasing number of Asian 
      countries; however, there is limited clinical experience in using the drug in 
      certain countries. Therefore, we established an Asian working group to provide 
      practical guidance for eribulin use based on our clinical experience. This paper 
      summarizes the key clinical trials, and the management recommendations for the 
      reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on 
      those that are relevant to Asian patients, followed by further elaboration of our 
      eribulin clinical experience. It is anticipated that this clinical practice guide 
      will improve the management of AEs resulting from eribulin treatment, which will 
      ensure that patients receive the maximum treatment benefit.
FAU - Ro, Jungsil
AU  - Ro J
AD  - Center for Breast Cancer, National Cancer Center, Goyang, Korea.
FAU - Cheng, Fiona Tsui-Fen
AU  - Cheng FT
AD  - Breast Cancer Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
FAU - Sriuranpong, Virote
AU  - Sriuranpong V
AD  - Division of Medical Oncology, Department of Medicine, King Chulalongkorn Memorial 
      Hospital, Chulalongkorn University, Bangkok, Thailand.
FAU - Villalon, Antonio
AU  - Villalon A
AD  - Department of Internal Medicine, Manila Doctor Hospital, Manila, Philippines.
FAU - Smruti, B K
AU  - Smruti BK
AD  - Division of Medical Oncology, Bombay Hospital Institute of Medical Sciences & 
      Lilavati Hospital, Mumbai, India.
FAU - Tsang, Janice
AU  - Tsang J
AD  - Department of Clinical Oncology, Queen Mary Hospital, The University of Hong 
      Kong, Hong Kong, China.
FAU - Yap, Yoon Sim
AU  - Yap YS
AD  - Department of Medical Oncology, National Cancer Centre Singapore, Singapore.
CN  - Asian Working Group for Eribulin Clinical Guide
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160325
PL  - Korea (South)
TA  - J Breast Cancer
JT  - Journal of breast cancer
JID - 101314183
PMC - PMC4822111
OTO - NOTNLM
OT  - Asians
OT  - Breast neoplasms
OT  - Chemotherapy
OT  - Eribulin mesylate
COIS- CONFLICT OF INTEREST: The authors declare that they have no competing interests.
EDAT- 2016/04/12 06:00
MHDA- 2016/04/12 06:01
PMCR- 2016/03/01
CRDT- 2016/04/12 06:00
PHST- 2015/12/10 00:00 [received]
PHST- 2016/02/18 00:00 [accepted]
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2016/04/12 06:01 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - 10.4048/jbc.2016.19.1.8 [doi]
PST - ppublish
SO  - J Breast Cancer. 2016 Mar;19(1):8-17. doi: 10.4048/jbc.2016.19.1.8. Epub 2016 Mar 
      25.